Johnson & Johnson’s Biosense Webster announced today that it launched the Octaray mapping catheter with TRUEref technology.
Irvine, California-based Biosense Webster designed Octaray for mapping cardiac arrhythmias, including AFib. It is powered by the company’s Carto 3 Version 7 system.
The catheter has eight splines with improved electrode spacing options, according to a news release. This offers shorter and more efficient mapping times compared to its Pentaray catheter. Increased efficiency and speed could shorten overall ablation procedure times, the company said.
Octaray can map arrhythmias in any chamber to quickly capture precise information ahead of catheter ablation procedures. TRUEref technology, a novel mapping reference electrode, reduces the impact of farfield signals. It helps to accurately identify lesion set gaps and improve the characterization of lesion sets.
“With more splines and electrodes, the increased surface area coverage and improved signal quality with the Octaray mapping catheter allows me to better understand the anatomy and conduction properties of the chamber of interest,” said Dr. Amit Thosani, director of cardiac electrophysiology at Allegheny Health Network. “This catheter not only helps me to map more accurately and efficiently, but also allows for better patient-specific therapy.”
Octaray with TRUEref technology is now available in the U.S. and EMEA.
“Building on Biosense Webster’s three decades of leadership in the science and technology of cardiac ablation, we are proud to bring forward the new Octaray mapping catheter with TRUEref technology as the newest mapping tool for electrophysiologists in the U.S. and EMEA,” said Michael Bodner worldwide president, Biosense Webster. “With shorter and more efficient mapping time, the catheter benefits both the patient and the physician, allowing for shorter procedure times while enabling greater accuracy and detail.”